Received Apr 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | U029623 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Z012131 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | W001494 | — |
No Side effects or symptoms reported; a 37-year-old female received their first dose of GARDASIL 9 in September 2022 (exact date unknown) and their second dose of GARDASIL 9 in December of 2022 (exact date unknown) but did not receive their third dose until 04/10/2026; This spontaneous report was received from a medical assistant and refers to a 37-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in September 2022, the patient was vaccinated with 1st dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection at a total dose of 0.5 mL, lot #U029623, expiration date: 26-OCT-2023 (route of administration and anatomical location were not reported), for prophylaxis. On an unspecified date in December 2022, the patient was vaccinated with 2nd dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection at a total dose of 0.5 mL, lot #W001494, expiration date: 15-SEP-2024 (route of administration and anatomical location were not reported), for prophylaxis. On 10-APR-2026, the patient was vaccinated with 3rd dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection at a total dose of 0.5 mL, lot #Z012131, expiration date: 02-JUL-2027 (route of administration and anatomical location were not reported), for prophylaxis (Inappropriate schedule of product administration). No side effects or symptoms were reported (No adverse event).